Previous 10 | Next 10 |
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, ...
2023-04-14 17:40:35 ET Summary Verve Therapeutics, Inc. is developing a CRISPR-based editing gene therapy for cardiovascular diseases. Verve's lead assets are VERVE-101 for HeFH and ASCVD and VERVE-201 for HoFH. On top of the overhang around VERVE-101's recent clinical hold fr...
2023-04-13 15:59:42 ET Shares of gene editing companies rose Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite the recent selloff. Notable gainers include Editas Medicine ( NASDAQ: EDIT ), Sangamo Therapeutics ( SG...
2023-04-13 13:49:46 ET Gene editing company Verve Therapeutics ( NASDAQ: VERV ) added ~11% on Thursday after Canaccord Genuity launched its coverage with a Buy rating and $29 per share target, citing a resolution to the clinical hold on the company’s lead asset VERVE-10...
BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
2023-03-05 16:46:05 ET Summary Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular diseases. The company’s research focuses on two genes, PCSK9 and ANGPTL3 - the lead product candidate, VERVE-101, aims to treat Heterozygou...
Gainers: A-Mark Precious Metals ( AMRK ) +6% . Absci ( ABSI ) +5% . Verve Therapeutics ( VERV ) +5% . Coherus BioSciences ( CHRS ) +5% . SouthState ( SSB ) +4% . Losers: Cytek Biosciences ( CTKB ) -12% . 2U ...
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the 2023 American College of Cardiolo...
Verve Therapeutics press release ( NASDAQ: VERV ): Q4 GAAP EPS of -$0.67 beats by $0.09 . Revenue of $1.01M beats by $0.57M . For further details see: Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporti...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...